Literature DB >> 16967312

Multilayered epithelium may be found in patients with Barrett's epithelium and dysplasia or adenocarcinoma.

Melissa P Upton1, Norman S Nishioka, Bernard J Ransil, Stanley J Rosenberg, William P Puricelli, Felice R Zwas, Helen M Shields.   

Abstract

To determine if multilayered epithelium (MLE) is a useful prognostic indicator for a benign natural history of Barrett's epithelium, we evaluated endoscopic biopsies from patients with Barrett's epithelium without and with dysplasia and/or adenocarcinoma and from non-Barrett's controls for the presence of MLE. MLE was found in 6% of non-Barrett's controls, 30% of Barrett's patients with no dysplasia, and 14% of Barrett's patients with dysplasia and/or adenocarcinoma. MLE was significantly associated with shorter lengths of Barrett's epithelium in both Barrett's groups. Three of 5 photodynamic therapy patients were noted to develop MLE after therapy. MLE may be found in patients with dysplasia and/or adenocarcinoma and after photodynamic therapy; its presence is not useful as a prognostic indicator for a more benign course of Barrett's. This study confirms that MLE is significantly associated with shorter lengths of Barrett's epithelium.

Entities:  

Mesh:

Year:  2006        PMID: 16967312     DOI: 10.1007/s10620-006-9243-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  54 in total

Review 1.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus?

Authors:  N J Shaheen; M A Crosby; E M Bozymski; R S Sandler
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.

Authors:  Chin Hur; Norman S Nishioka; G Scott Gazelle
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

3.  Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.

Authors:  M Menges; M Müller; M Zeitz
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

4.  Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.

Authors:  J N Glickman; A Yang; A Shahsafaei; F McKeon; R D Odze
Journal:  Hum Pathol       Date:  2001-11       Impact factor: 3.466

Review 5.  The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction.

Authors:  S J Spechler
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.

Authors:  F T Peters; S Ganesh; E J Kuipers; W J Sluiter; E C Klinkenberg-Knol; C B Lamers; J H Kleibeuker
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

7.  Correlation of oesophageal acid exposure with Barrett's oesophagus length.

Authors:  R Fass; R W Hell; H S Garewal; P Martinez; G Pulliam; C Wendel; R E Sampliner
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

8.  Adenocarcinoma of the esophagogastric junction and Barrett's esophagus.

Authors:  A J Cameron; C T Lomboy; M Pera; H A Carpenter
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

9.  Squamous metaplasia with reserve cell hyperplasia in the esophagogastric junction zone.

Authors:  K Takubo
Journal:  Acta Pathol Jpn       Date:  1981-05

10.  Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data.

Authors:  W K Hirota; T M Loughney; D J Lazas; C L Maydonovitch; V Rholl; R K Wong
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682

View more
  6 in total

1.  Exposure to both radiation and chemotherapy increases the risk of Barrett's and multilayered epithelium.

Authors:  Helen M Shields; Abram Recht; Helen H Wang
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

Review 2.  Barrett oesophagus: lessons on its origins from the lesion itself.

Authors:  Stuart A C McDonald; Danielle Lavery; Nicholas A Wright; Marnix Jansen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-04       Impact factor: 46.802

3.  Induction of MUC5AC mucin by conjugated bile acids in the esophagus involves the phosphatidylinositol 3-kinase/protein kinase C/activator protein-1 pathway.

Authors:  Shumei Song; James C Byrd; Sushovan Guha; Kai-Feng Liu; Dimpy Koul; Robert S Bresalier
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

4.  Multilayered epithelium at the gastroesophageal junction is a marker of gastroesophageal reflux disease: data from a prospective Central European multicenter study (histoGERD trial).

Authors:  Cord Langner; Eva-Maria Wolf; Wolfgang Plieschnegger; Michael Geppert; Bernd Wigginghaus; Gabriele M Höss; Andreas Eherer; Nora I Schneider; Peter Rehak; Michael Vieth
Journal:  Virchows Arch       Date:  2014-02-18       Impact factor: 4.064

5.  Ectopic Cdx2 expression in murine esophagus models an intermediate stage in the emergence of Barrett's esophagus.

Authors:  Jianping Kong; Mary Ann Crissey; Shinsuke Funakoshi; James L Kreindler; John P Lynch
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

6.  Multilayered epithelium in a rat model and human Barrett's esophagus: similar expression patterns of transcription factors and differentiation markers.

Authors:  Xiaoxin Chen; Rong Qin; Ba Liu; Yan Ma; Yinghao Su; Chung S Yang; Jonathan N Glickman; Robert D Odze; Nicholas J Shaheen
Journal:  BMC Gastroenterol       Date:  2008-01-11       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.